| Literature DB >> 2793805 |
B Birmaher, L L Greenhill, T B Cooper, J Fried, B Maminski.
Abstract
Methylphenidate is widely used in the treatment of school-age children with attention deficit disorder with hyperactivity (ADDH). It is available in a short-acting (MPH) and a long-acting (MPH-SR) preparation. Nine males with ADDH participated in a 1-day pharmacokinetic study following a single morning dose of 20 mg. MPH-SR. Data are presented on MPH-SR's half-life (T 1/2), peak concentrations achieved (Cmax) and the time to the peak plasma concentrations (Tmax). Similar data were gathered from a second group of eight ADDH males treated with a higher, single morning dose of standard, short-acting MPH. After adjusting for dose differences, comparisons of the two sets of plasma concentration curves suggest that MPH-SR has a longer Tmax, but that it does not reach the same Cmax as an identical dose of standard MPH.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2793805 DOI： 10.1097/00004583-198909000-00020
Source DB: PubMed Journal: J Am Acad Child Adolesc Psychiatry ISSN： 0890-8567 Impact factor: 8.829